trending Market Intelligence /marketintelligence/en/news-insights/trending/KomskNs5Hw_nlCIwfHG88Q2 content esgSubNav
In This List

Bioblast Pharma regains compliance with Nasdaq listing rule

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Bioblast Pharma regains compliance with Nasdaq listing rule

Bioblast Pharma Ltd. regained compliance with a Nasdaq listing rule that requires the company to maintain a minimum bid price of $1 per share.

After 10 consecutive business days following the company's 1-for-5 reverse stock split on Sept. 25, the closing bid price for Bioblast's ordinary shares was $1 per share or greater, the company said in a filing.